Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T13:25:24.761Z.
Calculation as of: 2026-10-06T13:25:24.761Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 236ecad6846b0cc00793ea2ceb9f38c60eee5e96b58175726d9ae7432cdeb63e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$675.41M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$709.33M
EV/EBIT Ratio
9.07x
TTM Avg
12.78x
3Y Avg
12.26x
5Y Avg
15.40x
Market Cap
$719.64M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$642.31M
EV/EBIT Ratio
N/A
TTM Avg
596.45x
3Y Avg
263.81x
5Y Avg
279.32x
Market Cap
$734.10M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Annexon, Inc. (ANNX) | $688.14M | N/A | N/A | N/A | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $698.60M | N/A | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $675.41M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $707.86M | N/A | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.33M | 9.07x | 12.78x | 12.26x | 15.40x |
| Achieve Life Sciences, Inc. (ACHV)vs › | $719.64M | N/A | N/A | N/A | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $643.37M | N/A | N/A | N/A | N/A |
| AngioDynamics, Inc. (ANGO)vs › | $642.31M | N/A | 596.45x | 263.81x | 279.32x |
| Anteris Technologies Global Corp. (AVR)vs › | $734.10M | N/A | N/A | N/A | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $637.59M | N/A | 2.85x | 52.42x | 52.42x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
